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ail address: antony.parker@bindingsite.co.uka b s t r a c tObjectives: Anti-pneumococcal capsular polysaccharide (PCP) IgM, IgG and IgA ELISAs
have been developed to aid assessment of the adaptive immune system. The relationship
between the concentrations of PCP IgM, IgG, and IgA was investigated.
Design and methods: The concentrations of PCP IgM, IgG, and IgA were measured in sera
obtained from 231 adult blood donors.
Results: Concentrations of each isotype were not normally distributed. The median con-
centration for PCP IgM was 54 U/mL (range 37–75 U/mL), IgG 40 mg/L (range 26–79 mg/L)
and IgA 21 U/mL (range 13–44 U/mL). The median PCP IgM titres decreased with age and
were significantly lower in patients aged 81–90 years compared to those aged 18–80 years. By
contrast, there was a significantly higher median serum PCP IgG titre in the 61–90 years
group compared to those aged 18–60 years and a significantly higher median serum PCP IgA
titre in the 51–90 years group compared to those aged 18–50 years. The correlation between
PCP IgG and IgA was more significant than between IgM and IgA and between IgM and IgG.
Correlation of PCP IgA and IgM concentrations identified four phenotypes: high PCP IgM and
IgA; high PCP IgM only; high PCP IgA only; and low PCP IgM and IgA. A significant number of
individuals with a PCP IgG concentration 450 mg/L had low PCP IgA and IgM concentrations.
Conclusion: The additional measurement of PCP IgA and PCP IgM, alongside PCP IgG, in in-
dividuals investigated for a compromised immune system may provide a more detailed an-
tibody profile.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Serum antibody measurements are used to assess immune system competence and recovery, and are included in
guidelines for the assessment of antibody deficiencies [1,5,7]. Commonly measured antibodies include those raised in re-
sponse to tetanus, haemophilus and pneumococcal capsular polysaccharide (PCP). Recently, the measurement of PCP IgM
and IgA has been reported in patients with common variable immunodeficiency (CVID) [3]. Cavaliere et al. identified four
PCP IgM and IgA phenotypes and assessed their concentrations retrospectively to stratify the risk of pneumonia and
bronchiectasis. At present, the measurement of antigen-specific IgA and IgM is not routinely performed for the assessment
of immunocompetence or risk of infection.
In this study we report the concentration of, and correlation between, PCP IgM, IgG, and IgA antibodies in a large cohort
of blood donor samples. We hypothesise that the simultaneous measurement IgA and IgM in addition to PCP IgG may give
the clinician a more detailed antibody profile for the assessment of immunocompetence.er B.V. This is an open access article under the CC BY license
(A.R. Parker).
Table 1
Age stratified median PCP IgM, IgG and IgA antibody titres and interquartile ranges.
Age stratified median antibody titre (interquartile range)
18–20 yrs 21–30 yrs 31–40 yrs 41–50 yrs 51–60 yrs 61–70 yrs 71–80 yrs 81–90 yrs
PCP IgM (U/mL) 65 57 54 46 56 50 44 27
(47–156) (45–81) (36–94) (32–72) (34–73)a (29–77) (28–83)a (14–52)a
Number of samples 12 78 18 37 25 29 21 11
PCP IgG (mg/L) 32 32 34 46 37 98 110 67
(17–49)a (22–54) (30–49) (27–76) (26–69) (28–168) (58–270) (48–117)
Number of samples 12 78 18 37 23 28 21 11
PCP IgA (U/mL) 20 19 21 24 28 35 43 55
(11–27)a (12–29) (12–27) (13–51) (15–67) (14–116) (43–96) (21–96)a
Number of samples 13 77 18 36 25 29 21 11
a These samples were determined to be normally distributed by Shapiro Wilk analysis.
A.R. Parker et al. / Practical Laboratory Medicine 5 (2016) 1–522. Materials and methods
2.1. Samples
Serum samples were obtained from 231 blood donors (125 males and 106 females) aged 18–90 years. Only subjects who
were free of recurrent infections or inflammation at the time of donation (assessed by questionnaire) and whose C-reactive
protein concentrations were o10 mg/L were included in the analysis. Samples were stored at 80 °C. The samples were
collected in donor centres by Biomex Solutions (Heidelberg, Germany) and purchased from Quest Biomedical (Solihull, UK).
Sample collection was approved by the Institution Ethics Review Board (#05142), with all donors providing written in-
formed consent.
2.2. Measurement of antigen-specific antibodies
Commercially available test kits (VaccZyme™ PCP Enzyme-Linked Immunosorbent Assays [ELISAs], The Binding Site
Group Limited, Birmingham, UK) were used to measure PCP IgM, IgG and IgA according to the manufacturer’s instructions.
All three ELISAs employ the use of capsular polysaccharide (CPS) absorption to improve the specificity of pneumococcal
antibody detection. The data obtained was stratified by age (Table 1) and median values and interquartile ranges (IQR) were
established for each age group. Median values were used to establish cut-offs for anti-PCP IgA and IgM, which were
compared to previously published cut-offs (20 U/mL and 150 U/mL respectively) for defining four phenotypic groups [3]. For
PCP IgG, the cut-off concentration of 50 mg/L was applied [4].
2.3. Statistical analysis
Shapiro–Wilk, Chi squared, Fisher’s exact and Mann Witney U tests were performed using Graphpad Prism software
(GraphPad Software, La Jolla, CA, USA). po0.05 was considered statistically significant.Fig. 1. Age-stratified concentrations of PCP IgM (U/mL), IgG (mg/L) and IgA (U/mL) in adult blood donors. Dotted lines represent median concentrations for
IgM (54 U/mL; black), IgG (40 mg/L; green) and IgA (21 U/mL; red). Box and Whisker plots show interquartile ranges, median, minimum and maximum
concentrations.
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The Shapiro–Wilk test for Gaussian distribution demonstrated that PCP IgM, IgG and IgA concentrations from adult blood
donors were not normally distributed (po0.0001). The median adult concentrations (18–90 years) and IQR ranges (25–75%)
were as follows: PCP IgM: median 54 U/ml, range 37–75 U/ml (n¼231); PCP IgG: median 40 mg/L, range 26–79 mg/L
(n¼228); and PCP IgA: median 21 U/ml, range 13–44 U/ml (n¼230).
Fig. 1 shows the age-stratified adult PCP IgM, IgG and IgA concentrations in normal blood donors. 51% (115/226) of
samples had a PCP IgM concentration greater than the median (54 U/mL). The median PCP IgM titres decreased with age and
there was a significantly lower median PCP IgM titre in patients aged 81–90 years (27 U/mL) compared to those aged 18–80
years (55 U/mL; p¼0.0017). 50% (114/226) of samples had a PCP IgG concentration greater than the median (40 mg/L). There
was a significantly higher median PCP IgG titre in the 61–70 years (98 mg/L; p¼0.0004), 71–80 years (110 mg/L; po0.0001),
and 81–90 years (67 mg/L; p¼0.018) groups compared to those aged 18–60 years (median 35 mg/L). For PCP IgA, 50% (113/
226) of samples had a concentration greater than the median (21 U/mL). There was a significantly higher median PCP IgA
titre in the 51–60 years (28 U/mL; p¼0.036), 61–70 years (35 U/mL; p¼0.0078), 71–80 years (43 U/mL; p¼0.0065), and 81–
90 years (55 U/mL; p¼0.0034) groups compared to those aged 18–50 years (median 20 U/mL). The age-specific con-
centration ranges for PCP IgM, IgG and IgA are shown in Table 1.
The correlation between PCP IgG and IgA was more significant (r¼0.45, po0.0001) than the correlation between IgM
and IgA (r¼0.2, p¼0.003), or between IgM and IgG (r¼0.012, p¼0.86) (Table 2). The number of samples with concentra-
tions above and below the medians was highly correlated between PCP IgG and IgA (po0.0001). When a concentration cut-
off of 50 mg/L was used for PCP IgG, PCP IgG and IgA were again highly correlated (po0.0001) (Table 3). When published
cut-offs were used for PCP IgM and PCP IgA levels (20 U/mL and 150 U/mL, respectively), the correlation between PCP IgG
and IgA was higher than the correlation between the other pairs.
Four phenotypes could be differentiated using median concentrations of PCP IgA and IgM (Fig. 2): (i) high PCP IgM and
IgA, (ii) high PCP IgM only, (iii) high PCP IgA only and (iv) low PCP IgM and IgA. The percentage of individuals with each
phenotype was similar. Separation of the samples by PCP IgA and IgM concentrations of 150 U/mL and 20 U/mL respectively
[3] significantly changed the number of individuals within each phenotypic group (high PCP IgM only4Low PCP IgM and
IgA4High PCP IgM and IgA4High PCP IgA only).
PCP IgA and IgM concentrations were measured in samples with a PCP IgG concentration450 mg/L (Fig. 3). 10–94% had
PCP IgA lower, 7–53% had PCP IgM lower and 7–15% of samples had a concentration of both PCP IgA and IgM lower than the
25th centile (lower IQR) of the normal range, the median values or the concentration cut offs previously reported [3].4. Discussion
Measurement of PCP antibody concentrations currently relies on the IgG isotype only whereas assessment should be
multi-isotypic to enable complete identification of a deficient antibody response. The purpose of this study was to de-
termine the isotype-specific antibody titres in age defined populations to provide a baseline for subsequent studies.
The production of PCP IgM is pivotal for the protection against pneumococcal disease [2,3,6] and has been shown to be
defective in CVID [3]. CVID patients with PCP IgA and IgM concentrations above 150 U/mL and 20 U/mL, respectively have
been shown to have a lower risk of developing pneumonia and bronchiectasis than those with either a PCP Ig
Mconcentrationo20 U/mL only or those with both concentrations below both the above cut-offs [3]. In this study, using the
same cut-offs in adult blood donors, the majority of individuals had a PCP IgM concentration420 U/mL. Schutz and col-
leagues [8] have previously reported an IgA and IgM response in all healthy individuals vaccinated with Pneumovax (8/10
PCP IgA4150 U/mL, with the 2/10o150 U/mL possessing a 45 fold increase in concentration post-vaccination, and 10/10
PCP IgM420 U/mL). Cavaliere reported that the pre-vaccination PCP IgM concentration in CVID patients was
10.2724.9 U/mL, and for PCP IgA 11.6729.1 U/mL. Using the baseline levels from this study a number of CVID patients may
have both IgM and IgA antibody levels lower that the base line concentration in the normal blood donor population.
The median concentration of PCP IgM antibodies decreased with age. The opposite was true of PCP IgG and IgA con-
centrations which were both stable up until approximately 60 years and then increased significantly from 61 to 90 years. ATable 2
Correlation between PCP IgM, IgG and IgA concentrations. Values top right of the grey boxes are from linear regression analysis. Values bottom left of the










PCP IgG p¼0.79 r¼0.45
po0.0001
PCP IgA p¼0.69 po0.0001
Table 3
Correlation between PCP IgM, IgG and IgA concentrations according to published cut-offs and median values. Values top right of the grey boxes are
produced using the following cutoffs: PCP IgM¼20 U/mL, PCP IgG¼50 mg/L and PCP IgA¼150 U/mL [3,4]. Values bottom left of the grey boxes are
produced using the median values for PCP IgM and IgA (54 U/mL and 21 U/mL, respectively) and 50 mg/L for PCP IgG. All values were obtained using the
Fisher's exact test.
Samples above or below published PCP IgM, IgG and IgA cut-offs [3,4]
Samples above or be-
low median con-
centrations (for PCP
IgM and IgA) or
50 mg/L (for PCP
IgG)










Fig. 2. Distribution of PCP IgM and IgA phenotypes according to median or published concentration cut-offs (n¼226). Median concentration cut-offs were
54 U/ml and 21 U/mL for PCP IgM and PCP IgA, respectively. Published concentration cut-offs were 20 U/mL and 150 U/mL for PCP IgM and PCP IgA,
respectively [3].
Fig. 3. Numbers and percentages of individuals with PCP IgG concentration450 mg/L (n¼97) but low PCP IgM and IgA concentrations. 25th centile (lower
IQR) concentration cut-offs were 37 U/mL and 13 U/mL for PCP IgM and PCP IgA, respectively. Median concentration cut-offs were 54 U/mL and 21 U/mL for
PCP IgM and PCP IgA, respectively. Published concentration cut-offs were 20 U/mL and 150 U/mL for PCP IgM and PCP IgA, respectively [3].
A.R. Parker et al. / Practical Laboratory Medicine 5 (2016) 1–54significant proportion of this older population are likely to have received a pneumococcal vaccination. Pneumovax™, which
was approved by the US Food and Drug Administration (FDA) in 1983, is recommended for US individuals aged 50 years.
Prevnar 7 and Prevnar 13 have been approved by the FDA more recently (in 2001 and 2010, respectively). Prior vaccination
or exposure to pneumococcal pathogens in this older population may be responsible for the elevated IgA and IgG titres.
By applying median concentrations of PCP IgM and PCP IgA as cut-off values, we differentiated 4 phenotypes, with
approximately equal distribution of individuals across each group (Fig. 2). Importantly, in 25% of individuals both PCP IgM
A.R. Parker et al. / Practical Laboratory Medicine 5 (2016) 1–5 5and PCP IgA concentrations were lower than the median values.
The measurement of PCP IgG is used to aid the diagnosis of an antibody deficiency and can be used to support the
selection of therapy or treatment in those individuals. In our study, a large percentage of adult blood donors with PCP
IgG450 mg/L possessed either low PCP IgM (7–53%) or both low PCP IgM and low PCP IgA (7–15%). A PCP IgG
concentration450 mg/L [4] did not always predict PCP IgM and IgA concentrations above the median values or published
cut-offs. The measurement of PCP IgM and IgA concentrations, in this population of individuals with PCP IgG450 mg/L,
would have further identified between 7 and 14 individuals with a higher risk of pneumococcal infection. Measurement of
PCP IgM and IgA may have particular utility for individuals with suspected antibody deficiency or those suffering from
recurrent infections, who present with PCP IgG levels greater than 50 mg/L.
In conclusion, we report reference ranges in adult blood donors for PCP IgM, IgG and IgA concentrations, and offer an
explanation for the trends observed. A substantial number of individuals in our population did not have PCP IgM, IgG or IgA
concentrations suggestive of protection from infection [2–4,6,9]. In particular, a number of individuals had PCP IgG450 mg/
L but low levels of PCP IgM and IgA. The addition of PCP IgM and PCP IgA to the panel of tests measured in individuals
investigated for a compromised immune system warrants further investigation.References
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